Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis

Journal of Urology

Volumn 188, Issue 6, 2012, Pages 2165-2170

  Busch, Jonas ^a   Hamborg, Kristin ^a   Meyer, Hellmuth Alexander ^a   Buckendahl, John ^a   Magheli, Ahmed ^a   Lein, Michael ^b,c   Jung, Klaus ^a,b   Miller, Kurt ^a   Stephan, Carsten ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c University Teaching Hospital   (Germany)

Author keywords

prognosis; prostatic neoplasms

Indexed keywords

PERCENT FREE PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84869091895     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.07.106     Document Type: Article

References (19)

1. L. Budaus, H. Isbarn, C. Eichelberg Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage J Urol 184 2010 1341
2. P.M. Pierorazio, T.J. Guzzo, M. Han Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen Urology 76 2010 715
3. M.W. Kattan, C. Yu, L. Salomon Development and validation of preoperative nomogram for disease recurrence within 5 years after laparoscopic radical prostatectomy for prostate cancer Urology 77 2011 396
4. T. Steuber, A.J. Vickers, A. Haese Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum Int J Cancer 118 2006 1234
5. S. Wenske, R. Korets, A.M. Cronin Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy Int J Cancer 124 2009 659
6. A. Magheli, S. Rais-Bahrami, B.J. Trock Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy J Urol 179 2008 1780
7. A. Magheli, S. Hinz, C. Hege Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience J Urol 183 2010 126
8. P.C. Southwick, W.J. Catalona, A.W. Partin Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial J Urol 162 1999 1346
9. W.J. Catalona, P.C. Southwick, K.M. Slawin Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging Urology 56 2000 255
10. P. Finne, A. Auvinen, L. Maattanen Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter Eur Urol 54 2008 362
11. A.A. Elabbady, M.M. Khedr Free/total PSA ratio can help in the prediction of high Gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml Int Urol Nephrol 38 2006 553
12. M. Graefen, P.I. Karakiewicz, I. Cagiannos Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy J Urol 167 2002 1306
13. C. Stephan, G. Stroebel, M. Heinau The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL Cancer 104 2005 993
14. A.V. D'Amico, J. Moul, P.R. Carroll Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era J Clin Oncol 21 2003 2163
15. S.W. Melchior, J. Noteboom, R. Gillitzer The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy BJU Int 88 2001 221
16. W.H. Henricks, B.G. England, D.A. Giacherio Serum percent-free PSA does not predict extraprostatic spread of prostate cancer Am J Clin Pathol 109 1998 533
17. H. Visapää, K. Hotakainen, J. Lundin The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy Urol Int 84 2010 378
18. R. Raaijmakers, S.H. de Vries, B.G. Blijenberg hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml Eur Urol 52 2007 1358
19. A. Kimura, S. Nakamura, M. Niizuma Quantitative analysis of ultrasonogram of the prostate J Clin Ultrasound 14 1986 501